Chapter 3 of 25
What you will learn
- Understand estrogen exposure, metabolism and inherited risk.
- Identify useful risk-reduction steps without promises.
- Know why symptoms still matter at any body size or age.
Hormones and the endometrium
Estrogen stimulates the uterine lining to grow. Progesterone normally balances that stimulation during ovulatory cycles. Long periods of estrogen exposure without adequate progesterone can increase the likelihood of hyperplasia and some endometrioid cancers. This may occur with infrequent ovulation, including some people with polycystic ovary syndrome, or with estrogen-only menopausal therapy when a uterus is present.
Menopausal hormone treatment should be individualized. People with a uterus generally need appropriate endometrial protection when using systemic estrogen. Vaginal low-dose preparations and systemic therapy are not interchangeable; discuss the actual product and symptoms with a clinician. Do not change a prescription based only on a general risk list.
Body weight and metabolic health
Higher amounts of body fat can increase estrogen production after menopause and are associated with insulin resistance and inflammation. Obesity and diabetes are associated with endometrial cancer risk, but these are complex biological and social conditions. Cancer also occurs in people without these factors. Weight stigma can delay diagnosis and should never be part of care.
Sustainable physical activity, balanced nutrition and appropriate diabetes management support general health. If weight management is a goal, ask for respectful, evidence-based support that accounts for medicines, mobility, finances and wellbeing. No diet guarantees prevention, and rapid weight loss during cancer treatment can be harmful. Prevention advice should not postpone assessment of bleeding.
Age, reproductive history and medicines
Risk rises with age, although premenopausal cases occur. Earlier onset of periods, later menopause and fewer pregnancies can be associated with a longer lifetime of endometrial stimulation. These are population associations, not reasons to make reproductive choices out of fear. Pregnancy and combined hormonal contraceptive use are associated with lower risk, but contraceptives have their own benefits, contraindications and adverse effects.
Tamoxifen can increase the risk of endometrial changes and cancer, particularly after menopause, while offering important benefits for appropriately selected breast cancer patients. Report abnormal bleeding promptly. Do not stop tamoxifen without discussing the balance of benefits and risks with the breast oncology team. Routine ultrasound screening in an asymptomatic average-risk tamoxifen user is not a substitute for symptom-led care.
Lynch syndrome and family history
Lynch syndrome is an inherited predisposition caused by a pathogenic variant in a DNA mismatch repair gene or certain EPCAM changes. It can increase risks of endometrial, colorectal and other cancers. Tumour testing can identify people who may need genetic counselling, even without a striking family history. A mismatch repair deficient tumour does not automatically mean inherited Lynch syndrome.
Tell the team about cancers in close relatives, their ages at diagnosis and known genetic results. Genetic counselling can explain testing, implications for relatives, privacy considerations and prevention choices. For confirmed carriers, surveillance and risk-reducing surgery discussions are individualized by gene, age and reproductive plans. The evidence for screening to prevent death is more limited than the evidence supporting risk-reducing surgery after childbearing in appropriate patients.
Practical prevention and misconceptions
| Helpful step | Important limit |
|---|---|
| Assess unexpected bleeding promptly | Symptoms cannot establish the diagnosis |
| Manage anovulation and endometrial protection | Treatment requires a clinician's assessment |
| Discuss family history and tumour MMR results | A tumour result is not a germline diagnosis |
| Maintain sustainable activity and metabolic care | Healthy habits cannot eliminate all risk |
Endometrial cancer is not contagious and is not evidence of poor hygiene or sexual behaviour. HPV vaccination remains valuable for other cancers but is not established prevention for endometrial cancer. Ask which risks change your follow-up and which are simply background information.
Related chapters
- Endometrial Hyperplasia and Precancer
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- NCI: Endometrial Cancer Prevention PDQ
- ACOG Clinical Consensus: EIN / atypical hyperplasia, 2023
- GeneReviews: Lynch Syndrome
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy